再鼎医药宣布呫诺美林曲司氯铵胶囊(I)/(II)/(III)与艾加莫德α注射液(皮下注射)首次纳入2026年国家医保药品目录

格隆汇
Yesterday
再鼎医药今日宣布,公司在国内的多款商业化产品被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2026)》。本次更新包括两款首次纳入的产品,提升了全身型重症肌无力(gMG)患者与精神分裂症患者的治疗可及性;以及三款续约产品,持续保障肿瘤和感染性疾病领域的用药可及性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10